[{"address1": "Emmy Noetherweg 2", "city": "Leiden", "zip": "2333 BK", "country": "Netherlands", "phone": "31 71 203 6410", "website": "https://pharvaris.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Mr. Berndt Axel Edvard Modig CPA, M.B.A.", "age": 64, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 594622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anna  Nijdam M.Sc., R.A.", "age": 42, "title": "Head of Strategic Finance & Principal Accounting Officer", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stefan  Abele Ph.D.", "age": 53, "title": "Chief Technology Operations Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annick  Deschoolmeester", "age": 50, "title": "Chief Human Resources Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peng  Lu M.D., Ph.D.", "age": 45, "title": "Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Anne A. Lesage Ph.D.", "age": 62, "title": "Chief Early Development Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Morgan  Conn Ph.D.", "age": 54, "title": "Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wim  Souverijns Ph.D.", "age": 52, "title": "Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David W. Nassif J.D.", "age": 69, "title": "CFO & Corporate Secretary", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Maryann  Cimino", "title": "Director of Corporate Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.31, "open": 17.78, "dayLow": 17.35, "dayHigh": 19.49, "regularMarketPreviousClose": 17.31, "regularMarketOpen": 17.78, "regularMarketDayLow": 17.35, "regularMarketDayHigh": 19.49, "beta": -3.103, "forwardPE": -6.0252366, "volume": 481825, "regularMarketVolume": 481825, "averageVolume": 69188, "averageVolume10days": 108360, "averageDailyVolume10Day": 108360, "bid": 19.05, "ask": 20.19, "bidSize": 100, "askSize": 100, "marketCap": 1031547072, "fiftyTwoWeekLow": 15.0, "fiftyTwoWeekHigh": 33.0, "fiftyDayAverage": 17.7536, "twoHundredDayAverage": 21.93025, "currency": "USD", "enterpriseValue": 591439488, "floatShares": 18856792, "sharesOutstanding": 54007700, "sharesShort": 129989, "sharesShortPriorMonth": 124094, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.09494001, "heldPercentInstitutions": 0.86619, "shortRatio": 2.71, "shortPercentOfFloat": 0.0031, "bookValue": 6.162, "priceToBook": 3.099643, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -114096072, "trailingEps": -2.89, "forwardEps": -3.17, "pegRatio": -0.28, "enterpriseToEbitda": -5.094, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PHVS", "underlyingSymbol": "PHVS", "shortName": "Pharvaris N.V.", "longName": "Pharvaris N.V.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "911cea00-0308-3cdf-8ed6-d47a5076b447", "gmtOffSetMilliseconds": -14400000, "currentPrice": 19.1, "targetHighPrice": 49.67, "targetLowPrice": 13.91, "targetMeanPrice": 32.22, "targetMedianPrice": 30.8, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 343574400, "totalCashPerShare": 6.362, "ebitda": -116103928, "totalDebt": 140378, "quickRatio": 18.136, "currentRatio": 18.447, "debtToEquity": 0.042, "returnOnAssets": -0.26791, "returnOnEquity": -0.45053002, "freeCashflow": -55186784, "operatingCashflow": -99276608, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]